Capital Markets

Goodwin’s unique combination of deep experience serving both the innovators and investors in a rapidly-changing, technology-driven economy sets us apart. We partner with clients to embrace the promise and potential of innovation to make a lasting impact. Our Debt Finance practice represents borrowers, private equity sponsors and lenders in a broad range of financing transactions. Our Debt Finance lawyers work closely with the firm's Private Equity, Technology Companies, Capital Markets, and Financial Restructuring groups structuring, negotiating and documenting domestic and cross-border debt financing arrangements, including secured and unsecured senior, mezzanine and subordinated debt facilities, acquisition-financing transactions, working capital facilities, as well as loan workouts and restructurings.

On the borrower side, Goodwin represents private equity firms and their portfolio companies, leading public and private companies and start-ups in a wide variety of business industries. On the lender side, Goodwin’s clients include domestic and international banks, insurance and finance companies, mezzanine lenders, business development companies and other institutional investors.

Succeeding in the life sciences industry is as much about strategy and execution as it is about research and development. And with the breakneck pace of technology disrupting industries on a global scale, Goodwin’s depth of experience not only in the life sciences space, but also in collaboration with our technology, healthcare, real estate and private equity lawyers, makes our team exceptionally suited to address whatever the future brings. We partner with clients to embrace the promise and potential of innovation to make a profound and lasting impact.

Goodwin’s fully integrated, globally recognized destination life sciences practice is dedicated to serving the needs of innovators and investors working collaboratively to improve patients' lives. Our team of more than 150 lawyers is devoted to life sciences companies across the entire company lifecycle, and team members are strategically located across the major life sciences hubs in the U.S., Europe and Asia.

When businesses need counsel at the intersection of real estate and the public markets, they turn to Goodwin, a proven leader and innovator. From the dawn of the REIT market in the 1960s through the modern REIT era that began in the early 1990s, our lawyers are the industry vanguard – helping to draft the Real Estate Investment Trust Act of 1960, pioneering the creation of the first public UPREIT structure, and successfully representing issuers in the largest and most complex REIT IPOs to date. And with the breakneck pace of technology disrupting industries around the world, we partner with our clients and embrace the promise and potential of innovation to make a lasting impact.

Goodwin has been consistently recognized as a leader serving the public REIT market, including in connection with alternative uses of the REIT vehicle, REIT conversions and innovative compensation structures like the modern LTIP partnership unit. As REITs have matured into a mainstream investment with expanded reach around the globe, the industry’s top players continue to rely on our expertise and dedication. And as REITs seek to take advantage of regulatory reforms that broaden their access to capital, such as new exemptions from registration or innovative equity securities, our lawyers are always first on the scene.

When a company is faced with a securities class action or shareholder derivative litigation, they need a partner who understands what is at stake and can think outside the box to achieve resolution. Goodwin’s deep experience, creative thinking and tenacity has led to our involvement in precedent-setting securities cases in courts across the country. The results we achieve are best of breed and have helped shape the law nationally, including outright dismissals of billions of dollars in putative class action and shareholder derivative claims. Our cases range from defending high tech and biotech companies in class action securities fraud litigation brought following restatements of earnings or the release of bad business news, to resolving shareholder derivative challenges, to multibillion dollar mergers and acquisitions.

As a growing technology company, your prospects are exciting and your challenges are unique – from securing funding, protecting IP, and navigating the regulatory environment, to differentiating yourself in the marketplace, managing customer acquisition and scaling your business. We get it. Our dedicated team brings a comprehensive, coordinated approach that interconnects business, new technologies and the law. Our depth of experience in the private equity space along with our technology, healthcare and life sciences lawyers makes Goodwin uniquely suited to harness the breakneck pace of technology. We partner with clients to embrace the promise and potential of innovation to make a profound and lasting impact.

As businesses today face an increasingly sophisticated threat environment compounded by aggressive regulatory enforcement, companies need a partner who can help mitigate risk and respond to the unthinkable. Our top ranked Data + Privacy + Cybersecurity practice is one of the longest-standing of any Am Law 50 firm. Our practice is fully integrated and leverages the firm's core strengths, with the group's lawyers coming from our technology, financial institutions, licensing, litigation, regulatory and appellate practices. Our unique approach, focusing on client needs and value, enables us to engage specialists whose experience is framed by a holistic understanding of clients' greatest risks in this threatening environment.

Special Purpose Acquisition Companies (SPACs) are newly-formed companies that raise capital in an initial public offering (IPO) for the sole purpose of using that capital to acquire assets or, more typically, one or more companies identified after the IPO. Our lawyers have a deep understanding of the legal, business, financial and marketing issues that affect the success of SPACs. We offer a global team, with lawyers in the U.S., Europe and Asia working collaboratively to assist clients with fast-track cross-border transactions.